Incidence of Status Migrainosus in Olmsted County, Minnesota, United States Characterization and Predictors of Recurrence

被引:4
作者
VanderPluym, Juliana H. [1 ]
Mangipudi, Kartik [1 ]
Mbonde, Amir Abdallah [1 ]
Gritsch, David [1 ]
Caronna, Edoardo [3 ]
Singh, Rashmi B. Halker B. [1 ]
Butterfield, Richard J. [2 ]
Smith, Jonathan H. [1 ]
机构
[1] Mayo Clin, Dept Neurol, Scottsdale, AZ 85259 USA
[2] Mayo Clin, Dept Quantitat Hlth Sci, Scottsdale, AZ USA
[3] Hosp Univ Vall dHebron, Neurol Dept, Barcelona, Spain
关键词
SOCIETY EVIDENCE ASSESSMENT; MEDICAL-RECORDS LINKAGE; HEADACHE; EPIDEMIOLOGY; PREVALENCE; POPULATION; BURDEN; ADULTS; DIAGNOSIS; PATTERNS;
D O I
10.1212/WNL.0000000000201382
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and ObjectivesSM is recognized as a complication of migraine in which pain and/or associated symptoms are unremitting and debilitating for more than 72 hours. The epidemiology of SM in the general population is not known. The aim of this study is to determine the incidence, recurrence rate, and clinical associations of status migrainosus (SM) in care-seeking residents of Olmsted County, Minnesota.MethodsThe Rochester Epidemiology Project was used to identify the incident cases of SM according to the International Classification of Headache Disorders, Third Edition criteria and based on the first physician-encountered case in the record. The clinical characteristics of the incident cases were abstracted from the medical record. One-year recurrence-free survival was evaluated and compared between clinically relevant groups, including baseline demographics, migraine characteristics, and treatment exposures.ResultsBetween January 1, 2012, and December 31, 2017, 237 incident cases of SM were identified. The median age was 35 (IQR 26-47) years, and 210 (88.6%) were female. A history of chronic migraine was recorded in 82/226 (36.3%) and a history of aura in 76/213 (35.7%). At the time of the incident case, medication reconciliation included a triptan or ergotamine in 127/233 (53.6%) and/or an opioid-containing analgesic in 43/233 (18.5%). The overall age- and sex-adjusted incidence rate was 26.60 per 100,000 [95% CI, 23.21-29.97], with a peak incidence between ages 40 and 49 years. The median (95% CI) attack duration was 5 (4.48-5.42) days. The most frequent triggers were stress (40/237, 16.9%) and too much or too little sleep (27/237, 11.4%). Recurrence occurred in 35/237 (14.8%) at a median of 58 (IQR 23-130) days following the initial attack. In our age- and sex-adjusted multivariable model, too much or too little sleep as a trigger was associated with 12-month risk of recurrence (adjusted OR 3.59 [95% CI 1.58-8.14], p = 0.0022).DiscussionOur study provides a population-based estimate of SM incidence. We identified aberrant sleep patterns as a potentially modifiable risk factor for 1-year SM recurrence.
引用
收藏
页码:E255 / E263
页数:9
相关论文
共 37 条
  • [1] Sex and gender: Opportunities to expand research and understanding within headache medicine
    Ackley, Elizabeth
    Halker Singh, Rashmi B.
    [J]. HEADACHE, 2022, 62 (07): : 771 - 773
  • [2] An Analysis of Migraine Triggers in a Clinic-Based Population
    Andress-Rothrock, Diane
    King, Wesley
    Rothrock, John
    [J]. HEADACHE, 2010, 50 (08): : 1366 - 1370
  • [3] [Anonymous], Sex and gender
  • [4] [Anonymous], US
  • [5] Status migrainosus and migraine aura status in a French tertiary-care center: An 11-year retrospective analysis
    Beltramone, Marion
    Donnet, Anne
    [J]. CEPHALALGIA, 2014, 34 (08) : 633 - 637
  • [6] Modifiable risk factors for migraine progression
    Bigal, Marcelo E.
    Lipton, Richard B.
    [J]. HEADACHE, 2006, 46 (09): : 1334 - 1343
  • [7] The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies
    Burch, Rebecca C.
    Loder, Stephen
    Loder, Elizabeth
    Smitherman, Todd A.
    [J]. HEADACHE, 2015, 55 (01): : 21 - 34
  • [8] Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO
  • [9] 2-F
  • [10] Centers for Disease Control and Prevention, About us